GlassScriptPhysician profile
Ravinder S Kohli
NPI 1659334373
$7,576.33
in general payments reported to CMS, 2019-2025
35 companies · $342 in 2025
The $342 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,075 · 2020: $1,361 · 2021: $1,389 · 2022: $757 · 2023: $1,638 · 2024: $1,014 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,867 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,866.58 |
| Education | $127.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,104.24 | 2021-2025 | Linq II, Reveal Linq, Corevalve Evolut R |
| Novartis Pharmaceuticals Corporation | $701.32 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $621.93 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $508.60 | 2019-2022 | |
| Amgen INC. | $407.84 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $388.01 | 2020-2024 | |
| Novo Nordisk INC | $374.48 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $358.60 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $356.69 | 2022-2024 | Verquvo |
| Abbott Laboratories | $355.82 | 2020-2025 | Mitraclip, Amplatzer Amulet |
| Edwards Lifesciences Corporation | $310.39 | 2019-2025 | Sapien 3 Ultra Resilia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $253.17 | 2019-2024 | Lifevest |
| Medtronic Vascular, INC. | $249.26 | 2019-2020 | |
| Pfizer INC. | $243.76 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $228.88 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $152.65 | 2023 | Opsumit, Uptravi |
| Medicomp INC | $145.22 | 2022-2024 | Telepatch Cardiac Monitor |
| Esperion Therapeutics, INC. | $124.28 | 2020-2021 | |
| Atricure, INC. | $83.63 | 2023 | |
| Impulse Dynamics (USA) INC. | $78.20 | 2022-2023 | Optimizer |
| Asahi Intecc USA, INC. | $71.99 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $67.55 | 2019 | |
| Kestra Medical Technology Services, INC. | $66.19 | 2022 | |
| Scpharmaceuticals INC. | $61.47 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $54.19 | 2023-2024 | Inpefa |
| Boston Scientific Corporation | $42.62 | 2023-2024 | Watchman Access System, Watchman Flx |
| Bardy Diagnostics, INC. | $37.96 | 2020 | |
| Inspire Medical Systems, INC. | $23.63 | 2023 | Inspire |
| Abiomed | $18.02 | 2024 | Impella |
| Chiesi USA, INC. | $16.99 | 2020 | |
| Gilead Sciences, INC. | $14.22 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.21 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.71 | 2021 | |
| Cardiva Medical, INC. | $13.39 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravinder Kohli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.